drugset / Trial / NCT00117455

A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma

NCT00117455

Phase 2 Completed Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the ability of two different fixed doses of pegfilgrastim (6mg and 12mg) and a by-weight dose of filgrastim (5ug/kg/day) for the mobilisation and collection of PBPCs for autologous transplantation after chemotherapy.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 6 mg
Subject Pegfilgrastim Protein / enzyme biologic 12 mg
Subject filgrastim Protein / enzyme biologic 5 ug/kg

Indications